CELL AND GENE THERAPY INSIGHTS

Filter by Interests

Filter by ContentType

European research infrastructures join forces to provide innovative cancer research services across Europe—how can they support the cell and gene therapy developer?

European research infrastructures join forces to provide innovative cancer research services across Europe—how can they support the cell and gene therapy developer?

E Oldoni, P Carvajal-Vallejos, F Bietrix et al
11 August 2023
Editorial
 Unproven stem cell-based interventions & harm to existing & future patients

Unproven stem cell-based interventions & harm to existing & future patients

Flora Naylor, Kirstin RW Matthews
27 March 2022
Editorial
 A model for where we live

A model for where we live

Jared Burks
25 November 2021
Editorial
 Mass cytometry for comprehensive immune profiling in CAR T cell

Mass cytometry for comprehensive immune profiling in CAR T cell

Sneha Ramakrishna
18 November 2021
Editorial
 Engineering new killers: bringing NK cells to the battle against cancer

Engineering new killers: bringing NK cells to the battle against cancer

Tamara J Laskowski, Sunil Acharya, Mayra Shanley
17 November 2021
Editorial
 Full spectrum flow cytometry: a powerful cytometric analysis to benefit cell therapy

Full spectrum flow cytometry: a powerful cytometric analysis to benefit cell therapy

Ana Leda Figueiredo Longhini
10 November 2021
Editorial
 CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Lisa A Michaels, MD, Bruce E Eaton, PhD
05 August 2021
Editorial
 Expanding gene therapy and gene editing strategies to large and complex indications

Expanding gene therapy and gene editing strategies to large and complex indications

Carmen Unzu, Florie Borel
30 June 2021
Editorial
 Alternative strategies for functionalizing CAR-T cells: engineering without genetic modification

Alternative strategies for functionalizing CAR-T cells: engineering without genetic modification

Carolyn Porter
19 May 2021
Editorial
 Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan?

Leading the way in bringing gene therapy to the CNS with conditioning: a renaissance for busulfan?

Chris Mason
22 October 2020
Editorial
 Need for regulatory compliance in research: what is Good Laboratory Practice and what is a validated assay?

Need for regulatory compliance in research: what is Good Laboratory Practice and what is a validated assay?

Lincoln Tsang
22 July 2019
Editorial
 Preclinical requirements for cell and gene therapies

Preclinical requirements for cell and gene therapies

Carlos R Plata-Salaman
22 July 2019
Editorial
 The immunosuppressive tumor microenvironment: more than just immune checkpoints

The immunosuppressive tumor microenvironment: more than just immune checkpoints

Mark Lowdell
04 July 2019
Editorial
 Critical considerations for allogeneic cell therapy scale up

Critical considerations for allogeneic cell therapy scale up

Sharon Grimster
18 December 2018
Editorial
 Update on the Sleeping Beauty transposon system for therapeutic applications

Update on the Sleeping Beauty transposon system for therapeutic applications

Suneel A Narayanavari
06 December 2018
Editorial
 Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

Marc Moore, John R Counsell
30 November 2018
Editorial
 Emerging Automated Approaches for Cell and Gene Therapy Manufacture

Emerging Automated Approaches for Cell and Gene Therapy Manufacture

Qasim Rafiq
20 November 2018
Editorial
 Changing the ‘Art’ of Growing Cells into an Industrialized Platform for Commercial-Scale Manufacturing

Changing the ‘Art’ of Growing Cells into an Industrialized Platform for Commercial-Scale Manufacturing

Lior Raviv
06 November 2018
Editorial
 Unique Role of Patient Advocacy Groups in Clinical Development of CGTx for Rare Diseases

Unique Role of Patient Advocacy Groups in Clinical Development of CGTx for Rare Diseases

Michelle Berg
16 October 2018
Editorial
 Developing Gene Therapy for CEP290-Associated Retinal Ciliopathies

Developing Gene Therapy for CEP290-Associated Retinal Ciliopathies

Hemant Khanna
02 October 2018
Editorial
 New Gene Therapy CMC Guidance from the FDA – A Breakthrough in Regulation or Something More Generic?

New Gene Therapy CMC Guidance from the FDA – A Breakthrough in Regulation or Something More Generic?

Anthony H Davies
15 August 2018
Editorial